Formerly known as BeiGene, the company changed its name in November 2024 as part of a broader strategic growth plan.  To support its expansive clinical portfolio and global growth, the company opened its $800 million flagship clinical R&D and manufacturing facility at the Princeton West Innovation Campus in Hopewell, N.J. in July 2024. The company’s stock ticker on Nasdaq will change to “ONC”.

Founded in 2010, the company specialises in novel drug discovery in the areas of both small molecules and biologicals, translational research with an emphasis on biomarker identification and validation in patients and bioinformatics based on human tumor genotyping and expression profiling.

With a broad portfolio, BeOne is expediting development of its diverse pipeline of novel therapeutics through internal capabilities and collaborations.